About QED Therapeutics
Who we are
A subsidiary of BridgeBio, QED focuses on precision medicine for FGFR-driven cancers and conditions. We live by our name: QED, derived from the Latin “Quod Erat Demonstrandum” —Thus, It Has Been Proven.
Our business is inspired by our values.
- Put patients first
- Think independently
- Be radically transparent
- EVERY MINUTE COUNTS
- LET SCIENCE SPEAK
QED Therapeutics has developed a strategic partnership with Helsinn to advance the oncology portfolio while maintaining sole ownership and development control of infigratinib for the treatment of achondroplasia. Future studies will investigate infigratinib for additional FGFR-driven tumor types and rare disorders.
FGFR=fibroblast growth factor receptor.